Skip to main content
SpringerLink
Log in

Renal Cell Carcinoma: Overview

  • Chapter
  • First Online:
Urological Oncology

Abstract

Renal cell carcinoma is histologically heterogeneous and can be considered as a group of closely related but distinct tumour types that differ in histopathology and genetic findings. In most cases renal tumours occur sporadically but a minority occur in individuals with an inherited predisposition to kidney cancer and, sometimes, other tumours. Knowledge of the molecular basis of inherited kidney tumours has provided important insights into the key cellular pathways that are disordered in the pathogenesis of kidney cancer. Here we review the relationship between aetiology, histopathology and molecular characteristics of differing subtypes of renal cell carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kovacs G, Akhtar M, Beckwith BJ, Bugert P, et al. The Heidelberg classification of renal cell tumours. J Pathol. 1997;183:131–3.

    Article  CAS  PubMed  Google Scholar 

  2. AJCC. Kidney. In: Edge SB, Byrd DR, Compton CC, et al., editors. Cancer staging manual. 7th ed. New York: Springer; 2010. p. 479–89.

    Google Scholar 

  3. Delahunt B. Advances and controversies in grading and staging of renal cell carcinoma. Mod Pathol. 2009;22 Suppl 2:S24–36.

    Article  PubMed  Google Scholar 

  4. Hock LM, Lynch J, Balaji KC. Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis of surveillance, epidemiology and end results program data. J Urol. 2002;167:57–60.

    Article  PubMed  Google Scholar 

  5. Delahunt B, Bethwaite PB, Nacey JN. Outcome prediction for renal cell carcinoma: evaluation of prognostic factors for tumours divided according to histological subtype. Pathology. 2007;39:459–65.

    Article  CAS  PubMed  Google Scholar 

  6. Bonsib SM. Renal lymphatics, and lymphatic involvement in sinus vein invasive (pT3b) clear cell renal cell carcinoma: a study of 40 cases. Mod Pathol. 2006;19:746–53.

    Article  PubMed  Google Scholar 

  7. Mai KT, Landry DC, Robertson SJ, et al. A comparative study of metastatic renal cell carcinoma with correlation to subtype and primary tumor. Pathol Res Pract. 2011;197:671–5.

    Article  Google Scholar 

  8. Cho HJ, Kim SJ, Ha US, et al. Prognostic value of capsular invasion for localized clear-cell renal cell carcinoma. Eur Urol. 2009;56:1006–12.

    Article  PubMed  Google Scholar 

  9. Waldert M, Haitel A, Marberger M, et al. Comparison of type I and II papillary renal cell carcinoma (RCC) and clear cell RCC. BJU Int. 2008;102:1381–4.

    PubMed  Google Scholar 

  10. Margulis V, Tamboli P, Matin SF, Swanson DA, Wood CG. Analysis of clinicopathologic predictors of oncologic outcome provides insight into the natural history of surgically managed papillary renal cell carcinoma. Cancer. 2008;112:1480–8.

    Article  PubMed  Google Scholar 

  11. Klatte T, Han KR, Said JW, et al. Pathobiology and prognosis of chromophobe renal cell carcinoma. Urol Oncol. 2008;26:604–9.

    Article  PubMed  Google Scholar 

  12. Abdollah F, Sun M, Thuret R, et al. Mortality and morbidity after cytoreductive nephrectomy for metastatic renal cell carcinoma: a population-based study. Ann Surg Oncol. 2011;18:2988–96.

    Article  PubMed  Google Scholar 

  13. Robson JS. Advances in the treatment of renal disease. Practitioner. 1969;203:483–93.

    CAS  PubMed  Google Scholar 

  14. Maher ER. Genetics of familial renal cancers. Nephron Exp Nephrol. 2011;118:e21–6.

    Article  PubMed  Google Scholar 

  15. Linehan WM, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol. 2010;7:277–85.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  16. Pavlovich CP, Walther MM, Eyler RA, Hewitt SM, et al. Renal tumors in the Birt-Hogg-Dubé syndrome. Am J Surg Pathol. 2002;26:1542–52.

    Article  PubMed  Google Scholar 

  17. Ricketts C, Woodward ER, Killick P, Morris MR, et al. Germline SDHB mutations and familial renal cell carcinoma. J Natl Cancer Inst. 2008;100:1260–2.

    Article  CAS  PubMed  Google Scholar 

  18. Latif F, Tory K, Gnarra J, Yao M, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993;260:1317–20.

    Article  CAS  PubMed  Google Scholar 

  19. Banks RE, Tirukonda P, Taylor C, Hornigold N, et al. Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res. 2006;66:2000–11.

    Article  CAS  PubMed  Google Scholar 

  20. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399:271–5.

    Article  CAS  PubMed  Google Scholar 

  21. Kaelin Jr WG. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res. 2007;13:680s–4.

    Article  CAS  PubMed  Google Scholar 

  22. Beroukhim R, Brunet JP, Di NA, Mertz KD, et al. Patterns of gene expression and copy-number alterations in von-Hippel Lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res. 2009;69:4674–81.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Varela I, Tarpey P, Raine K, Huang D, et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature. 2011;469:539–42.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Dalgliesh GL, Furge K, Greenman C, Chen L, et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature. 2010;463:360–3.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. Schmidt L, Duh FM, Chen F, Kishida T, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet. 1997;16:68–73.

    Article  CAS  PubMed  Google Scholar 

  26. Schmidt L, Junker K, Nakaigawa N, Kinjerski T, et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene. 1999;18:2343–50.

    Article  CAS  PubMed  Google Scholar 

  27. Toro JR, Nickerson ML, Wei MH, Warren MB, et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet. 2003;73:95–106.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. Kovacs G, Fuzesi L, Emanual A, Kung HF. Cytogenetics of papillary renal cell tumors. Genes Chromosomes Cancer. 1991;3:249–55.

    Article  CAS  PubMed  Google Scholar 

  29. Furge KA, Chen J, Koeman J, Swiatek P, et al. Detection of DNA copy number changes and oncogenic signalling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma. Cancer Res. 2007;67:3171–6.

    Article  CAS  PubMed  Google Scholar 

  30. Macher-Goeppinger S, Roth W, Wagener N, Hohenfellner M, et al. Molecular heterogeneity of TFE3 activation in renal cell carcinomas. Mod Pathol. 2012;25(2):308–15. doi:10.1038/modpathol.2011.169.

    CAS  PubMed  Google Scholar 

  31. Speicher MR, Schoell B, du MS, Schrock E, Ried T, et al. Specific loss of chromosomes 1, 2, 6, 10, 13, 17, and 21 in chromophobe renal cell carcinomas revealed by comparative genomic hybridization. Am J Pathol. 1994;145:356–64.

    CAS  PubMed Central  PubMed  Google Scholar 

  32. Gad S, Lefevre SH, Khoo SK, Giraud S, et al. Mutations in BHD and TP53 genes, but not in HNF1beta gene, in a large series of sporadic chromophobe renal cell carcinoma. Br J Cancer. 2007;96:336–40.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  33. Toro JR, Wei MH, Glenn GM, Weinreich M, et al. BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dube syndrome: a new series of 50 families and a review of published reports. J Med Genet. 2008;45:321–31.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  34. Menko FH, van Steensel MA, Giraud S, Friis-Hansen L, Richard S, et al. European BHD Consortium. Birt-Hogg-Dubé syndrome: diagnosis and management. Lancet Oncol. 2009;10:1199–206.

    Article  CAS  PubMed  Google Scholar 

  35. Polascik TJ, Cairns P, Epstein JI, Fuzesi L, et al. Distal nephron renal tumors: microsatellite allelotype. Cancer Res. 1996;56:1892–5.

    CAS  PubMed  Google Scholar 

  36. Compton CC, Byrd DR, Garcia-Aguilar J, et al. Kidney. In: Compton CC, Byrd DR, Garcia-Aguilar J, et al., editors. AJCC cancer staging atlas. New York: Springer; 2012. p. 557–66.

    Chapter  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical and Molecular Genetics, IBR, University of Birmingham, Birmingham, UK

    Christopher J. Ricketts PhD

  2. Department of Medical Genetics, University of Cambridge, Box 238, Cambridge, CB2 0QQ, UK

    Eamonn R. Maher BSc, MD, FRCP, FMedSci

Authors
  1. Christopher J. Ricketts PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eamonn R. Maher BSc, MD, FRCP, FMedSci
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eamonn R. Maher BSc, MD, FRCP, FMedSci .

Editor information

Editors and Affiliations

  1. Department of Urology, Homerton University Hospital & Formerly St. Bartholomew's Hospital, London, United Kingdom

    Vinod H. Nargund

  2. Levine Cancer Institute, Carolinas HealthCare System, Charlotte, North Carolina, USA

    Derek Raghavan

  3. Radiation Oncology, Cedars Sinai Cancer Center, Los Angeles, California, USA

    Howard M. Sandler

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag London

About this chapter

Cite this chapter

Ricketts, C.J., Maher, E.R. (2015). Renal Cell Carcinoma: Overview. In: Nargund, V., Raghavan, D., Sandler, H. (eds) Urological Oncology. Springer, London. https://doi.org/10.1007/978-0-85729-482-1_17

Download citation

  • DOI: https://doi.org/10.1007/978-0-85729-482-1_17

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-0-85729-481-4

  • Online ISBN: 978-0-85729-482-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation